对刺激性免疫检查点诱导共刺激分子（ICOS）的苦苦思索。
Agonizing over the Stimulatory Immune Checkpoint ICOS.
作者信息
Lee Jerry C, Fong Lawrence
机构信息
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
出版信息
Clin Cancer Res. 2022 Sep 1;28(17):3633-3635. doi: 10.1158/1078-0432.CCR-22-1520.
Abstract
Vopratelimab, an anti-ICOS (inducible costimulator of T cells) agonist, alone and in combination with nivolumab, possesses limited toxicity and modest clinical activity in a large phase I/II trial. This treatment induced ICOS expression of CD4+ T cells, which may enable biomarkers for patient selection. Nevertheless, T-cell agonists as cancer immunotherapies continue to be challenging. See related article by Yap et al., p. 3695.
摘要
沃普拉替单抗是一种抗ICOS（T细胞诱导共刺激分子）激动剂，在一项大型I/II期试验中，其单独使用及与纳武单抗联合使用时，毒性有限且临床活性适度。这种治疗诱导了CD4+ T细胞的ICOS表达，这可能有助于筛选患者的生物标志物。然而，T细胞激动剂作为癌症免疫疗法仍然具有挑战性。见Yap等人的相关文章，第3695页。
相似文献
1
Agonizing over the Stimulatory Immune Checkpoint ICOS.对刺激性免疫检查点诱导共刺激分子（ICOS）的苦苦思索。
Clin Cancer Res. 2022 Sep 1;28(17):3633-3635. doi: 10.1158/1078-0432.CCR-22-1520.
2
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.首次人体 I 期/II 期 ICONIC 试验：ICOS 激动剂 Vopratelimab 单药及联合 Nivolumab 治疗：ICOS 高 CD4 T 细胞群体及反应预测因子。
Clin Cancer Res. 2022 Sep 1;28(17):3695-3708. doi: 10.1158/1078-0432.CCR-21-4256.
3
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.诱导共刺激因子 (ICOS) 作为一种潜在的抗肿瘤治疗靶点。
Expert Opin Ther Targets. 2018 Apr;22(4):343-351. doi: 10.1080/14728222.2018.1444753. Epub 2018 Mar 1.
4
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.在临床前模型中，ICOS 激动剂 JTX-2011（vopratelimab）需要初始 T 细胞致敏和 Fc 交联，以实现最佳的 T 细胞激活和抗肿瘤免疫。
PLoS One. 2020 Sep 24;15(9):e0239595. doi: 10.1371/journal.pone.0239595. eCollection 2020.
5
Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.在犬白细胞抗原非匹配造血细胞移植后慢性移植物抗宿主病中活化 T 细胞上诱导共刺激分子（ICOS）的上调：一个潜在的治疗靶点。
Transplantation. 2013 Jul 15;96(1):34-41. doi: 10.1097/TP.0b013e318295c025.
6
Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD.抗 ICOS mAb 靶向慢性移植物抗宿主病犬模型中致病性表达 IL-17A 的细胞。
Transplantation. 2021 May 1;105(5):1008-1016. doi: 10.1097/TP.0000000000003489.
7
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.ICOS+ CD4 T 细胞频率升高可作为抗 CTLA-4 治疗的药效生物标志物。
Cancer Immunol Res. 2013 Oct;1(4):229-34. doi: 10.1158/2326-6066.CIR-13-0020. Epub 2013 Jul 31.
8
Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.诱导共刺激因子（ICOS）在癌症免疫治疗中的作用。
Expert Opin Biol Ther. 2020 Feb;20(2):141-150. doi: 10.1080/14712598.2020.1693540. Epub 2019 Nov 28.
9
ICOS agonist vopratelimab modulates follicular helper T cells and improves B cell function in common variable immunodeficiency.ICOS 激动剂 vopratelimab 调节滤泡辅助 T 细胞并改善普通可变免疫缺陷中的 B 细胞功能。
Clin Immunol. 2024 Jul;264:110217. doi: 10.1016/j.clim.2024.110217. Epub 2024 Apr 14.
10
Targeting inducible costimulator expressed on CXCR5PD-1 T cells suppresses the progression of pemphigus vulgaris.针对表达在 CXCR5+PD-1 T 细胞上的诱导共刺激分子抑制寻常型天疱疮的进展。
J Allergy Clin Immunol. 2020 Nov;146(5):1070-1079.e8. doi: 10.1016/j.jaci.2020.03.036. Epub 2020 Apr 18.
引用本文的文献
1
Directed evolution and modular integration of a high-affinity ICOS-L variant for potent T cell-mediated tumor elimination.用于高效T细胞介导的肿瘤消除的高亲和力ICOS-L变体的定向进化和模块化整合。
J Biol Eng. 2025 Jul 11;19(1):63. doi: 10.1186/s13036-025-00536-6.
2
Post-translational modifications of cancer immune checkpoints: mechanisms and therapeutic strategies.癌症免疫检查点的翻译后修饰：机制与治疗策略
Mol Cancer. 2025 Jul 8;24(1):193. doi: 10.1186/s12943-025-02397-5.
3
The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1CD8 T cells.共刺激分子ICOS限制耗竭性PD-1⁺CD8⁺ T细胞的记忆样特性和功能。
Immunity. 2025 Jul 1. doi: 10.1016/j.immuni.2025.06.001.
4
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.ICOS 共刺激与 CTLA-4 阻断联合重塑肿瘤相关巨噬细胞向抗肿瘤表型。
J Exp Med. 2024 Apr 1;221(4). doi: 10.1084/jem.20231263. Epub 2024 Mar 22.
5
Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.EB 病毒编码的 EBNA2 通过诱导 miR-24 在 B 细胞淋巴瘤中下调 ICOSL。
Blood. 2024 Feb 1;143(5):429-443. doi: 10.1182/blood.2023021346.
6
ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade.ICOS基因的DNA甲基化调控黑色素瘤细胞内在的ICOS表达，与黑色素瘤的分化、预后相关，并可预测对免疫检查点阻断的反应。
Biomark Res. 2023 Jun 1;11(1):56. doi: 10.1186/s40364-023-00508-2.
本文引用的文献
1
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.首次人体 I 期/II 期 ICONIC 试验：ICOS 激动剂 Vopratelimab 单药及联合 Nivolumab 治疗：ICOS 高 CD4 T 细胞群体及反应预测因子。
Clin Cancer Res. 2022 Sep 1;28(17):3695-3708. doi: 10.1158/1078-0432.CCR-21-4256.
2
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.MIW815（ADU-S100），一种肿瘤内 STING 激动剂，在晚期/转移性实体瘤或淋巴瘤患者中的 I 期剂量递增试验。
Clin Cancer Res. 2022 Feb 15;28(4):677-688. doi: 10.1158/1078-0432.CCR-21-1963.
3
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.先前存在的免疫状态与转移性去势抵抗性前列腺癌患者接受 sipuleucel-T 和 ipilimumab 联合治疗的反应相关。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002254.
4
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.在临床前模型中，ICOS 激动剂 JTX-2011（vopratelimab）需要初始 T 细胞致敏和 Fc 交联，以实现最佳的 T 细胞激活和抗肿瘤免疫。
PLoS One. 2020 Sep 24;15(9):e0239595. doi: 10.1371/journal.pone.0239595. eCollection 2020.
5
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).肿瘤炎症特征（TIS）定义的泛癌适应性免疫抵抗：来自癌症基因组图谱（TCGA）的结果。
J Immunother Cancer. 2018 Jun 22;6(1):63. doi: 10.1186/s40425-018-0367-1.
6
The promise and challenges of immune agonist antibody development in cancer.免疫激动剂抗体在癌症中的前景与挑战。
Nat Rev Drug Discov. 2018 Jul;17(7):509-527. doi: 10.1038/nrd.2018.75. Epub 2018 Jun 15.
7
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.ICOS 通路的参与显著增强了 CTLA-4 阻断在癌症免疫治疗中的疗效。
J Exp Med. 2014 Apr 7;211(4):715-25. doi: 10.1084/jem.20130590. Epub 2014 Mar 31.
8
Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison.肿瘤微环境中的浆细胞样树突状细胞与调节性T细胞：一种危险的关联
Oncoimmunology. 2013 May 1;2(5):e23887. doi: 10.4161/onci.23887.
9
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.ICOS/ICOSL 通路是抗 CTLA-4 治疗介导的抗肿瘤反应的最佳途径。
Cancer Res. 2011 Aug 15;71(16):5445-54. doi: 10.1158/0008-5472.CAN-11-1138. Epub 2011 Jun 27.
10
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.术前 CTLA-4 阻断：术前临床试验中耐受性和免疫监测。
Clin Cancer Res. 2010 May 15;16(10):2861-71. doi: 10.1158/1078-0432.CCR-10-0569. Epub 2010 May 11.
Zotero 插件